Related references
Note: Only part of the references are listed.The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model
Xiaozhu Li et al.
CLINICAL CANCER RESEARCH (2017)
Science in Focus - Oncolytic Viruses: New Multifunctional Immunotherapeutics
H. S. Pandha
CLINICAL ONCOLOGY (2016)
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Igor Puzanov et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Combinatorial approach to cancer immunotherapy: strength in numbers
Anna E. Vilgelm et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies
Laura Evgin et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers
Tuuli Ranki et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
From Benchtop to Bedside: A Review of Oncolytic Virotherapy
Audrey H. Choi et al.
BIOMEDICINES (2016)
TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response
Jianfeng Han et al.
CANCER RESEARCH (2015)
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Jonathan Pol et al.
ONCOIMMUNOLOGY (2015)
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
Christine E. Engeland et al.
MOLECULAR THERAPY (2014)
Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies
Samuel T. Workenhe et al.
MOLECULAR THERAPY (2014)
A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses
James M. Markert et al.
MOLECULAR THERAPY (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity
Zong Sheng Guo et al.
FRONTIERS IN ONCOLOGY (2014)
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Andrew M. Intlekofer et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Oncolytic viruses as therapeutic cancer vaccines
David L. Bartlett et al.
MOLECULAR CANCER (2013)
Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma
Shohei Miyamoto et al.
CANCER RESEARCH (2012)
Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
Eleni M. Karapanagiotou et al.
CLINICAL CANCER RESEARCH (2012)
Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα
I-K Choi et al.
GENE THERAPY (2011)
A Comparative Study of Neural and Mesenchymal Stem Cell-Based Carriers for Oncolytic Adenovirus in a Model of Malignant Glioma
Atique U. Ahmed et al.
MOLECULAR PHARMACEUTICS (2011)
Neural Stem Cell-based Cell Carriers Enhance Therapeutic Efficacy of an Oncolytic Adenovirus in an Orthotopic Mouse Model of Human Glioblastoma
Atique U. Ahmed et al.
MOLECULAR THERAPY (2011)
Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy
Paul T. Sobol et al.
MOLECULAR THERAPY (2011)
Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer
Jun Li et al.
MOLECULAR THERAPY (2011)
Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study
J. Garcia-Castro et al.
CANCER GENE THERAPY (2010)
Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck
Kevin J. Harrington et al.
CLINICAL CANCER RESEARCH (2010)
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma
F. Galivo et al.
GENE THERAPY (2010)
Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma
Bita Boozari et al.
GUT (2010)
Potentiating Cancer Immunotherapy Using an Oncolytic Virus
Byram W. Bridle et al.
MOLECULAR THERAPY (2010)
Advances in mesenchymal stem cell-mediated gene therapy for cancer
Roisin M. Dwyer et al.
STEM CELL RESEARCH & THERAPY (2010)
Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model
Emily K. Mader et al.
CLINICAL CANCER RESEARCH (2009)
Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo
M. A. Tyler et al.
GENE THERAPY (2009)
The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon
Robin J. Prestwich et al.
HUMAN GENE THERAPY (2009)
The changing face of neural stem cell therapy in neurologic diseases
Ofira Einstein et al.
ARCHIVES OF NEUROLOGY (2008)
Oncolytic viruses: a novel form of immunotherapy
Robin J. Prestwich et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo
Jennifer Altomonte et al.
MOLECULAR THERAPY (2008)
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Roberto Cattaneo et al.
NATURE REVIEWS MICROBIOLOGY (2008)
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis
Thi Lien-Anh Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy
Kazuhiko Kurozumi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow
Caroline J. Breitbach et al.
MOLECULAR THERAPY (2007)
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus
Rosa Maria Diaz et al.
CANCER RESEARCH (2007)
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
Ta-Chiang Liu et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
History of oncolytic viruses: Genesis to genetic engineering
Elizabeth Kelly et al.
MOLECULAR THERAPY (2007)
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
Giulia Fulci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Synergistic antitumor effects of immune cell-viral biotherapy
SH Thorne et al.
SCIENCE (2006)
Recent progress in the battle between oncolytic viruses and tumours
KA Parato et al.
NATURE REVIEWS CANCER (2005)
Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas
E Galanis et al.
GENE THERAPY (2005)
Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients
J Nemunaitis et al.
CANCER GENE THERAPY (2003)
Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
D Kirn et al.
NATURE MEDICINE (2001)
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
FR Khuri et al.
NATURE MEDICINE (2000)
Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant
K Ikeda et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
